See full prescribing information for yorvipath. Yorvipath is indicated for the treatment of hypoparathyroidism in adults The fda has approved yorvipath (palopegteriparatide) injection for subcutaneous use in adults with hypoparathyroidism Conventional therapy for hypoparathyroidism consists of active vitamin d (e.g., calcitriol or its analog alfacalcidol) and calcium supplementation. Yorvipath (palopegteriparatide) is a prescription injection that treats hypoparathyroidism in adults, learn about dosage, side effects, cost, uses, and more.
WATCH
